Efficacy and Safety of ETX 018810 in Subjects With Lumbosacral Radicular Pain

• Status: Recruiting
• Trial end date: 2021-10-30
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eliem Therapeutics (UK) Ltd.

Criteria

Inclusion Criteria:

• The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy due to injury of the lumbosacral nerve root(s)

• The subject reports at least moderate pain intensity at screening.

• The subject's onset of leg pain due to LSRP is at least 3 months

• The subject has a magnetic resonance imaging (MRI) scan that is normal or shows incidental lesions

• The subject has a calculated creatinine clearance ≥30 mL/min

• The subject has clinical laboratory values within normal limits or abnormal values that the investigator deems not clinically significant.

• body mass index (BMI) <40 kg/m2.

Exclusion Criteria:

• The subject has previously undergone back surgery

• The subject is unable to reliably delineate or assess pain by anatomical location/distribution on a body map.

• The subject has a history of peripheral neuropathy, evidence of peripheral neuropathy, or evidence of mononeuropathy in the same limb of LSRP.

• The subject has pain due to infection/abscess, hematoma, or malignancy or other pain that may interfere with the assessment of LSRP in the legs.

• The subject has clinically significant and/or unstable renal, hepatic, hematologic, endocrine, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study

• The subject has any neurological disease that could interfere with participation in the study (e.g., Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, seizures, epilepsy, stroke).

• The subject has a history or current diagnosis of major psychiatric disorder(s)

• The subject has a has a history of substance abuse or dependence

• The subject has clinically significant abnormal electrocardiogram (ECG) findings

• The subject has received nerve blocks and/or steroid injections for LSRP within the 3 months before screening

• The subject is unwilling or unable to discontinue current medications for LSRP, including topical agents.

• The subject is unable to refrain from using prohibited meds during the study, including: NSAID, antiepileptic drugs, steroids, cannabinoids, or major opioids, antidepressants, muscle relaxants, tramadol, or tapentadol.

• The subject has used prohibited nonpharmacologic therapies, including acupuncture, transcutaneous electrical nerve stimulation, within 30 days the study.

• The subject is currently participating in another or the same clinical study or participated in another clinical study within 3 months before screening

• The subject is pregnant or lactating or not practicing adequate birth control